Insmed Incorporated
Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About INSM
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline.
INSM Key Statistics
Stock Snapshot
With a market cap of 42.99B, Insmed Incorporated(INSM) trades at $201.63. The stock has a price-to-earnings ratio of -32.62.
During the trading session on 2025-11-19, Insmed Incorporated(INSM) shares reached a daily high of $203.65 and a low of $195.51. At a current price of $201.63, the stock is +3.1% higher than the low and still -1.0% under the high.
Trading volume for Insmed Incorporated(INSM) stock has reached 2.39M, versus its average volume of 2.01M.
The stock's 52-week range extends from a low of $60.40 to a high of $203.65.
The stock's 52-week range extends from a low of $60.40 to a high of $203.65.
INSM News
Insmed Incorporated recently announced that the European Commission has approved BRINSUPRI (brensocatib 25 mg tablets) for treating non-cystic fibrosis bronchie...
New insider activity at Insmed ( (INSM) ) has taken place on November 18, 2025. Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make...
Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...
Analyst ratings
95%
of 19 ratingsMore INSM News
Insmed (INSM) Incorporated announced that the European Commission has approved BRINSUPR for the treatment of non-cystic fibrosis bronchiectasis in patients 12 y...
Insmed (INSM) has recently drawn attention as its stock showed a major jump in recent weeks, outpacing the broader biotech sector. Investors are considering wha...